

## NIPRO Strengthens Americas Presence with Trade Name Change to Nipro Americas Group

NIPRO CORPORATION today announced that its consolidated subsidiary, Nipro Holdings Americas, Inc. (Head office: Miami, Florida, USA; CEO: Akira Shimizu), has changed its trade name to Nipro Americas Group Companies, Inc., effective August 1, 2025.

The Americas are one of NIPRO's fastest-growing regions, contributing significantly to the company's overseas sales, which now exceed 50% of total revenues. The new name reflects NIPRO's strategy to strengthen its regional headquarters, ensuring stronger governance, streamlined compliance, and closer alignment with global standards, including regulatory affairs, to better understand and respond quickly to market needs and changes of the region.

This change highlights the importance of the Americas within NIPRO's global vision. By uniting under the Nipro Americas Group Companies name, NIPRO is reinforcing its commitment to customers, partners, and patients across the region."

Under the "ONE NIPRO" philosophy, the company will continue to expand its presence, invest in education and partnerships, and promote the NIPRO brand globally.

### Subsidiary Overview

- (1) Trade name: Nipro Americas Group Companies, Inc.
- (2) Location: Miami, Florida, USA
- (3) Date of trade name change: August 1, 2025
- (4) Business: Regional headquarters for governance, compliance, and business support across North and Latin America



---

#### About NIPRO CORPORATION

NIPRO CORPORATION (Head office: Osaka, Japan) is a leading global healthcare company with operations in over 60 countries. Its diverse portfolio spans renal care, hospital products, pharmaceuticals, PharmaPackaging, vascular solutions, cardiopulmonary devices, and regenerative medicine. NIPRO's mission is to be a true global healthcare company that aims to improve patient outcomes and contribute to a better quality of life for all.

Official website (<https://www.nipro.co.jp/en/>)

Instagram (<https://www.instagram.com/wearenipro>)

This news release is meant to provide information on NIPRO's corporate activities and an overview of our initiatives to not only the press but also our many stakeholders, including shareholders and investors in a fair and timely manner.

The information about NIPRO products and services included in this release is not intended for use in attracting customers or as medical advice.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.